熱門資訊> 正文
Vertex报告Inaxaplin治疗肾脏疾病的中期结果呈阳性
2026-09-22 23:24
- Vertex Pharmaceuticals (VRTX) said that data from a phase 2b trial found that the experimental drug inaxaplin led to a significant decline in proteinuria in individuals with APOL1-mediated kidney disease (AMKD).
- Results from the AMPLIFIED study showed that in one cohort, people with AMKD with modest proteinuria had a 42.7% reduction in urine albumin-to-creatinine ratio (UACR) at week 13 compared to baseline. A secondary endpoint, urine protein-to-creatinine ratio (UPCR), showed a 44.7% drop.
- In the second cohort, individuals with AMKD, type 2 diabetes, and proteinuria, UACR reduction was 17.3%, while UPCR declined 25.4%.
- Vertex noted that it is on schedule to release data from a pre-planned interim analysis of the phase 2/3 AMPLITUDE study in early 2027.
More on Vertex Pharmaceuticals
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
- Vertex trades higher after JPM gives bullish rating
推薦文章
美股前瞻 | 霍爾木茲海峽或7天內重開！國際油價齊挫，三大期指轉升；美聯儲「二把手」今夜發言；阿里雲棲大會加碼AI基建及自研芯片
Meta點燃半導體、CPU「超級行情」！英特爾年內勁升超230%，AI硬件還有哪些標的獲看好？
華盛早報 | 兩大利好引爆芯片股！英特爾大漲12%，AMD市值破萬億美元；Muse智能體助推Meta飆升11%；阿里雲棲大會今日開幕
美股前瞻 | 中美高層會談釋放積極信號！納指期貨升逾1%；比特幣再度站上8.5萬美元；英特爾盤前升逾5%，佈局先進封裝劍指光通信賽道
新股申購 | 四隻新股今起招股！PCB龍頭景旺電子、直驅機器人公司本末科技、羅博特科、彤程新材在列
港股異動 | 創新葯概念集體走高，英派藥業-B飆漲逾27%，榮昌生物、康方生物、信達生物漲逾6%，藥明生物漲逾5%
華盛早報 | 中美經貿磋商正在紐約進行！特朗普引爆資源股！GLND夜盤飆升119%；景旺電子等四隻新股今起招股
港股周報 | 加息落地！科技股企穩反彈，恆生科指漲近2%；利潤率比肩戴爾？聯想周漲20%再創新高
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
